{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:53:13Z","timestamp":1789689193997,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University-Industry Research Cooperation Project of Science and Technology","award":["2024Y41010089"],"award-info":[{"award-number":["2024Y41010089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16098-9","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:44:04Z","timestamp":1778251444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade"],"prefix":"10.1186","volume":"26","author":[{"given":"Fuqun","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"16098_CR1","doi-asserted-by":"publisher","first-page":"102584","DOI":"10.1016\/j.ctrv.2023.102584","volume":"118","author":"BM Meyers","year":"2023","unstructured":"Meyers BM, Knox JJ, Liu DM, McLeod D, Ramjeesingh R, Tam VC, Lim HJ. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review. Cancer Treat Rev. 2023;118:102584.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"16098_CR2","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"20","key":"16098_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"10408","key":"16098_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet (London England). 2023;402(10408):1133\u201346.","journal-title":"Lancet (London England)"},{"key":"16098_CR5","doi-asserted-by":"crossref","unstructured":"Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI insight. 2019;4(6):e126908.","DOI":"10.1172\/jci.insight.126908"},{"issue":"1","key":"16098_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, Chen X, Zhang B, Liang H, Liu D, et al. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79(1):109\u201325.","journal-title":"J Hepatol"},{"key":"16098_CR7","doi-asserted-by":"publisher","first-page":"115955","DOI":"10.1016\/j.biopha.2023.115955","volume":"170","author":"C Guo","year":"2024","unstructured":"Guo C, Zhou N, Lu Y, Mu M, Li Z, Zhang X, Tu L, Du J, Li X, Huang D, et al. FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2024;170:115955.","journal-title":"Biomed pharmacotherapy = Biomedecine pharmacotherapie"},{"issue":"5","key":"16098_CR8","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, et al. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. Hepatology (Baltimore MD). 2021;74(5):2544\u201360.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"16098_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","volume":"41","author":"SL Chan","year":"2022","unstructured":"Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, et al. A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J experimental Clin cancer research: CR. 2022;41(1):189.","journal-title":"J experimental Clin cancer research: CR"},{"issue":"1","key":"16098_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41423-023-01112-y","volume":"21","author":"F Luo","year":"2024","unstructured":"Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, et al. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cell Mol Immunol. 2024;21(1):60\u201379.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"16098_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J experimental Clin cancer research: CR. 2025;44(1):145.","journal-title":"J experimental Clin cancer research: CR"},{"key":"16098_CR12","doi-asserted-by":"publisher","first-page":"1390453","DOI":"10.3389\/fimmu.2024.1390453","volume":"15","author":"L Shen","year":"2024","unstructured":"Shen L, Li Y, Zhao H. Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases. Front Immunol. 2024;15:1390453.","journal-title":"Front Immunol"},{"issue":"6","key":"16098_CR13","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1021\/acs.jmedchem.8b01531","volume":"62","author":"X Lu","year":"2019","unstructured":"Lu X, Chen H, Patterson AV, Smaill JB, Ding K. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. J Med Chem. 2019;62(6):2905\u201315.","journal-title":"J Med Chem"},{"issue":"14","key":"16098_CR14","first-page":"1846","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinf (Oxford England). 2007;23(14):1846\u20137.","journal-title":"Bioinf (Oxford England)"},{"issue":"W1","key":"16098_CR15","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"16098_CR16","first-page":"100625","volume":"5","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innov (Cambridge (Mass). 2024;5(3):100625.","journal-title":"Innov (Cambridge (Mass)"},{"key":"16098_CR17","doi-asserted-by":"crossref","unstructured":"Hu FF, Liu CJ, Liu LL, Zhang Q, Guo AY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform. 2021;22(3):bbaa176.","DOI":"10.1093\/bib\/bbaa176"},{"issue":"D1","key":"16098_CR18","doi-asserted-by":"publisher","first-page":"D1526","DOI":"10.1093\/nar\/gkae1100","volume":"53","author":"C Huang","year":"2025","unstructured":"Huang C, Liu Z, Guo Y, Wang W, Yuan Z, Guan Y, Pan D, Hu Z, Sun L, Fu Z, et al. scCancerExplorer: a comprehensive database for interactively exploring single-cell multi-omics data of human pan-cancer. Nucleic Acids Res. 2025;53(D1):D1526\u201335.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"16098_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2025;20(1):180\u2013219.","journal-title":"Nat Protoc"},{"issue":"11","key":"16098_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, Rambow F, Marine JC, Geurts P, Aerts J, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083\u20136.","journal-title":"Nat Methods"},{"issue":"7","key":"16098_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"16098_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, Srivastava A, Molla G, Madad S, Fernandez-Granda C, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42(2):293\u2013304.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"16098_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M, Loh PR, Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16(12):1289\u201396.","journal-title":"Nat Methods"},{"issue":"D1","key":"16098_CR24","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 2025;53(D1):D672\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"16098_CR25","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Cambridge (Mass). 2021;2(3):100141.","journal-title":"Innov (Cambridge (Mass)"},{"issue":"9","key":"16098_CR26","doi-asserted-by":"publisher","first-page":"43996","DOI":"10.31083\/FBL43996","volume":"30","author":"EDG Fleuren","year":"2025","unstructured":"Fleuren EDG. One Size Does Not Fit All: Precision Combinations for FGFR4-driven Cancers. Front bioscience (Landmark edition). 2025;30(9):43996.","journal-title":"Front bioscience (Landmark edition)"},{"key":"16098_CR27","doi-asserted-by":"crossref","unstructured":"Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 Signaling in hepatocellular carcinoma. Cells. 2019;8(6):536.","DOI":"10.3390\/cells8060536"},{"key":"16098_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","volume":"15","author":"M Locati","year":"2020","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2020;15:123\u201347.","journal-title":"Annu Rev Pathol"},{"key":"16098_CR29","doi-asserted-by":"publisher","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front Immunol. 2022;13:888713.","journal-title":"Front Immunol"},{"issue":"1","key":"16098_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, Zhang H, Zhu M, Tian L, Wang X, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25(1):102\u201316.","journal-title":"Nat Immunol"},{"issue":"1","key":"16098_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41420-023-01424-y","volume":"9","author":"H Zhao","year":"2023","unstructured":"Zhao H, Wei S, Zhou D, Liu Y, Guo Z, Fang C, Pang X, Li F, Hou H, Cui X. Blocking the CXCL1-CXCR2 axis enhances the effects of doxorubicin in HCC by remodelling the tumour microenvironment via the NF-\u03baB\/IL-1\u03b2\/CXCL1 signalling pathway. Cell death discovery. 2023;9(1):120.","journal-title":"Cell death discovery"},{"key":"16098_CR32","doi-asserted-by":"publisher","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet (London, England). 2017;389:2492-502. https:\/\/doi.org\/10.1016\/s0140-6736(17)31046-2.","DOI":"10.1016\/s0140-6736(17)31046-2"},{"key":"16098_CR33","doi-asserted-by":"crossref","unstructured":"Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligiblepatients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2017;389:67-76.","DOI":"10.1016\/S0140-6736(16)32455-2"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16098-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:41:08Z","timestamp":1781793668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16098-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16098"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16098-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (MTCA, ECFAH of FMU [2015]084\u2009\u2212\u20093) and was conducted in accordance with the Declaration of Helsinki. The requirement for individual informed consent was waived owing to the retrospective design of the study and the use of de-identified patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"759"}}